Vital Therapies ditches $75M IPO; BioMarin, Myriad partner up on cancer drug;

@FierceBiotech: FDA sets up roadblock for Forest, Richter, rejecting #schizophrenia drug. Story | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline politely dumps $230M Fabry drug deal with Amicus. News | Follow @JohnCFierce

@DamianFierce: Icahn buys into Hologic; Hologic swallows 10% poison pill. Release | Follow @DamianFierce

@EmilyMFierce: Imagining the Post-Antibiotics Future. Feature (via Medium) | Follow @EmilyMFierce

> Vital Therapies is the latest in a growing list of biotechs that couldn't quite make the IPO finish line, postponing a $75 million pitch designed to fund a liver failure treatment. Story

> BioMarin Pharmaceutical ($BMRN) is teaming up with Myriad Genetics ($MYGN) to find ideal targets for an in-development cancer drug. Article

> Novartis ($NVS) is touting some positive early results for its novel H7N9 avian influenza vaccine. News

Medical Device News

@FierceMedDev: Medtronic scores promising results for next-gen stent graft. Story | Follow @FierceMedDev

@MarkHFierce: A Belgian company snagged some new funding for an interesting ophthalmic device, tech spun out of a Seattle outfit. Item | Follow @MarkHFierce

@MichaelGFierce: FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. More | Follow @MichaelGFierce

> Myriad partners up with BioMarin for cancer diagnostics. Article

> OraSure dumps Roche for Thermo Fisher in drug abuse Dx development deal. News

> Slumping Hologic downs poison pill as Icahn looms. Report

Pharma News

@FiercePharma: Wednesday's best-read story (still): Will Teva find a partner to save it from itself? More | Follow @FiercePharma

@EricPFierce: 350 sales folks get the ax as Actavis trims US force post Warner Chilcott merger. Story | Follow @EricPFierce

@CarlyHFierce: Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer. Release | Follow @CarlyHFierce

> Vimizim panel nod fuels new BioMarin buyout buzz. Story

> Forest's antipsychotic ambitions thwarted by FDA delay. More

> Pfizer whacks plant as generics eat sales. News

Vaccines News

> European Union prepares to back vaccine stability project. News

> China's climate diversity creates flu vaccination complications. More

> WHO updates malaria roadmap with 2030 vaccine goals. Article

> U.S. gathers vaccine researchers to talk bioterrorism threat Q fever. Story

> CDC to import unapproved Novartis vaccine to stem Princeton meningitis outbreak. Piece

Pharma Manufacturing News

> JLL lines up financing for $2.6B Patheon, DSM deal. More

> GE Oslo plant gets FDA OK for new heart imaging product. News

> Pfizer to close Puerto Rico plant. Story

> Actavis puts California plant on hit list. Article

> Unilife grabs $40M contract to fill Hikma injectables. More

Suggested Articles

The ambitious target is enabled by an AI discovery platform that Healx thinks gives it a scalability that has more in common with tech than biotech.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.